Expert opinion by Federation of Obstetric and Gynaecological Societies of India on elagolix - Redefining the endometriosis therapy landscape.
Endometriosis is a substantial public health challenge, affecting nearly 10% of women of reproductive age. Given the therapeutic benefits of elagolix over conventional therapies, along with the growing body of …
Non-Mineral Antioxidant Supplementation in Endometriosis: Biological Rationale, Clinical Evidence, and Therapeutic Implications-A Narrative Review.
Background/Objectives: Oxidative stress plays an important role in the pathophysiology of endometriosis, contributing to inflammation, immune dysregulation, and lesion progression. This has led to growing interest in antioxidant-based strategies as …
Is colorectal resection necessary to improve pain and fertility outcomes in patients with deep endometriosis?
Bowel endometriosis is often considered an indication for extensive surgical management, including colorectal resection, in women undergoing surgery for concomitant endometriosis at other sites. However, several contemporary studies show little …
Role of soluble EGFR, Fas, and Fas ligand in pelvic pain severity and their association with endometriosis in infertile woman: a case-control study.
Endometriosis, a chronic inflammatory condition linked to pelvic pain and infertility, is characterized by immune dysfunction involving dysregulated apoptosis and cell proliferation. This case-control study included 87 infertile women undergoing …
Primary emotional systems and personality functioning in women with endometriosis receiving brief psychotherapy: a longitudinal study using ANPS and SWAP-200.
Endometriosis is a chronic gynecological condition often associated with severe pelvic pain, reduced quality of life, and significant psychological and sexual distress. Although psychological factors are known to influence pain …
Linzagolix, with and without add-back therapy, in women with endometriosis-associated pain: results from EDELWEISS 6, a double-blind randomized extension and withdrawal study.
Was the efficacy of linzagolix, observed at 6 months in women with endometriosis-associated pain, maintained when administered for an additional 6 months?